CY1111654T1 - Θεραπευτικη αγωγη πλαγιας μυατροφικης σκληρυνσης - Google Patents

Θεραπευτικη αγωγη πλαγιας μυατροφικης σκληρυνσης

Info

Publication number
CY1111654T1
CY1111654T1 CY20101101011T CY101101011T CY1111654T1 CY 1111654 T1 CY1111654 T1 CY 1111654T1 CY 20101101011 T CY20101101011 T CY 20101101011T CY 101101011 T CY101101011 T CY 101101011T CY 1111654 T1 CY1111654 T1 CY 1111654T1
Authority
CY
Cyprus
Prior art keywords
treatment
therapeutic administration
relates
administration treatment
als
Prior art date
Application number
CY20101101011T
Other languages
English (en)
Inventor
Peter Carmeliet
Original Assignee
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw filed Critical Vib Vzw
Publication of CY1111654T1 publication Critical patent/CY1111654T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Automatic Cycles, And Cycles In General (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με την θεραπευτική αγωγή ασθενειών κινητικών νευρώνων. Ειδικότερα η εφεύρεση σχετίζεται με την θεραπευτική αγωγή πλάγιας μυατροφικής σκλήρυνσης (ALS: amyotrophic lateral sclerosis). Βρέθηκε ότι η ενδοεγκεφαλοκοιλιακή χορήγηση μικρών ποσοτήτων αγγειακού ενδοθηλιακού αυξητικού παράγοντα σε προκλινικό ζωικό πρότυπο πλάγιας μυατροφικής σκλήρυνσης επάγει σημαντική κινητική επίδοση και παράταση χρόνου επιβίωσης αυτών των ζώων.
CY20101101011T 2004-05-27 2010-11-10 Θεραπευτικη αγωγη πλαγιας μυατροφικης σκληρυνσης CY1111654T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102334 2004-05-27
EP05747975A EP1755647B1 (en) 2004-05-27 2005-05-27 Treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
CY1111654T1 true CY1111654T1 (el) 2015-10-07

Family

ID=34968798

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101011T CY1111654T1 (el) 2004-05-27 2010-11-10 Θεραπευτικη αγωγη πλαγιας μυατροφικης σκληρυνσης

Country Status (17)

Country Link
US (2) US7687463B2 (el)
EP (1) EP1755647B1 (el)
JP (2) JP5537770B2 (el)
AT (1) ATE478678T1 (el)
AU (1) AU2005249234B2 (el)
CA (1) CA2568158A1 (el)
CY (1) CY1111654T1 (el)
DE (1) DE602005023155D1 (el)
DK (1) DK1755647T3 (el)
ES (1) ES2351804T3 (el)
HR (1) HRP20100555T1 (el)
ME (1) ME01870B (el)
PL (1) PL1755647T3 (el)
PT (1) PT1755647E (el)
RS (1) RS51481B (el)
SI (1) SI1755647T1 (el)
WO (1) WO2005117946A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277528B1 (en) * 2000-04-12 2014-11-12 Vib Vzw Use of VEGF and homologues to treat neuron disorders
WO2005117946A1 (en) * 2004-05-27 2005-12-15 Vib Vzw Treatment of amyotrophic lateral sclerosis
WO2012048330A2 (en) * 2010-10-08 2012-04-12 The Mclean Hospital Corporation Treatment of motor neuron disease
CA2881464C (en) 2012-08-07 2021-12-21 Children's Medical Center Corporation Potassium channel openers for treating neurodegenerative diseases
EP2719407A1 (en) * 2012-10-09 2014-04-16 EU Sol Biotech Co., Ltd. Kit for treating brain injury or stroke
JP6474795B2 (ja) * 2013-10-01 2019-02-27 カディマステム リミテッド 薬物スクリーニング及び筋萎縮性側索硬化症（ａｌｓ）の処置における使用のための、ヒト多能性幹細胞からのアストロサイトの指向性分化
KR20230138815A (ko) * 2022-03-24 2023-10-05 주식회사 아이엔테라퓨틱스 인비보 패치 클램프 기법을 이용한 전기생리학적 약효 평가법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
CZ250499A3 (cs) 1997-01-17 1999-11-17 Rhone-Poulenc Rorer S. A. Použití nukleové kyseliny k indukci inervace svalů a růstu axonů motorických neuronů
WO1999046364A1 (en) 1998-03-13 1999-09-16 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
JP4532733B2 (ja) 1998-03-17 2010-08-25 ジェネンテック， インコーポレイテッド Ｖｅｇｆおよびｂｍｐ１と相同なポリペプチド群
CN1319139A (zh) 1998-09-23 2001-10-24 牛津生物医学（英国）有限公司 多聚核苷酸构建体及其应用
US7125856B1 (en) 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
WO2000062798A2 (en) 1999-04-15 2000-10-26 St. Elizabeth's Medical Center, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
EP2277528B1 (en) 2000-04-12 2014-11-12 Vib Vzw Use of VEGF and homologues to treat neuron disorders
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
JP2006502240A (ja) * 2002-10-04 2006-01-19 オックスフォード バイオメディカ （ユーケー） リミテッド ベクター系
WO2005117946A1 (en) * 2004-05-27 2005-12-15 Vib Vzw Treatment of amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
AU2005249234B2 (en) 2010-08-05
HRP20100555T1 (hr) 2011-01-31
JP2008500312A (ja) 2008-01-10
JP2012111774A (ja) 2012-06-14
SI1755647T1 (sl) 2011-01-31
JP5537770B2 (ja) 2014-07-02
ES2351804T3 (es) 2011-02-10
RS51481B (en) 2011-04-30
US20080279906A1 (en) 2008-11-13
US20100152116A1 (en) 2010-06-17
EP1755647B1 (en) 2010-08-25
US7863246B2 (en) 2011-01-04
DK1755647T3 (da) 2010-10-11
PL1755647T3 (pl) 2011-01-31
ME01870B (me) 2011-04-30
WO2005117946A1 (en) 2005-12-15
US7687463B2 (en) 2010-03-30
CA2568158A1 (en) 2005-12-15
ATE478678T1 (de) 2010-09-15
PT1755647E (pt) 2010-09-29
DE602005023155D1 (de) 2010-10-07
EP1755647A1 (en) 2007-02-28
AU2005249234A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
CY1111654T1 (el) Θεραπευτικη αγωγη πλαγιας μυατροφικης σκληρυνσης
ECSP11011173A (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
NO20065227L (no) Menoklonale antistoff mot hepatocytt vekstfaktor
ECSP12012020A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ECSP11011554A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes.
IL172705A0 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
NO20071798L (no) Dermalt pafore formuleringer for behandling av hudsykdommer i dyr
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
EA200800075A1 (ru) Схема дозирования для празугреля
DE602005007611D1 (de) Nahrungsmittelzusatz
ATE516366T1 (de) Regulierte aptamer-therapeutika
WO2006053788A3 (en) Alterations in seborrheic keratoses and their applications
RU2008152376A (ru) Средство против вируса ящура для животных, относящихся к семейству свиней или овец, и способы профилактики и лечения ящура у животных, относящихся к семейству свиней или овец
ATE460431T1 (de) Nicht-neutralisierende anti-apc-antikörper
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
ATE482706T1 (de) Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
DE60330233D1 (de) Arsentherapie zur behandlung von autoimmunerkrankungen
EA200801023A1 (ru) Применение фенофибрата или его производного для предотвращения диабетической ретинопатии
DK1838392T3 (da) Selenholdige medikamenter mod endotheliale vaskulære sygdomme